Citadel Advisors
CNTX icon

Citadel Advisors’s Context Therapeutics CNTX Stock Holding History

Citadel Advisors’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.6K Sell
17,338
-122,679
-88% -$249K ﹤0.01% 13501
2026
Q1 		$367K Buy
140,017
+105,637
+307% +$247K ﹤0.01% 10012
2025
Q4 		$50.5K Sell
34,380
-68,983
-67% -$80.6K ﹤0.01% 12030
2025
Q3 		$100K Buy
+103,363
New +$83.8K ﹤0.01% 11851
2025
Q1 		– Sell
-29,900
Closed -$31.4K – 14602
2024
Q4 		$31.4K Buy
+29,900
New +$51.7K ﹤0.01% 12830
2024
Q2 		– Sell
-15,041
Closed -$20.8K – 14376
2024
Q1 		$20.8K Sell
15,041
-839
-5% -$944 ﹤0.01% 12994
2023
Q4 		$17.9K Buy
15,880
+5,442
+52% +$5.85K ﹤0.01% 12715
2023
Q3 		$15.8K Buy
+10,438
New +$11.8K ﹤0.01% 12809
2022
Q2 		– Sell
-18,516
Closed -$40K – 12996
2022
Q1 		$40K Buy
+18,516
New +$38.9K ﹤0.01% 12928

Other funds holding CNTX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Citadel Advisors's CNTX Position: Q2 2026 in Review

Citadel Advisors reduced its Context Therapeutics (CNTX) stake by 88% in Q2 2026, selling an estimated $249K and leaving 17,338 shares worth $9.6K. The position accounts for ﹤0.01% of the portfolio, ranked #13501.

Citadel Advisors first reported a position in CNTX in Q1 2022 and has held it in 9 quarters since. The position peaked at $367K in Q1 2026. 79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • Citadel Advisors held 17,338 shares of Context Therapeutics worth $9.6K as of Q2 2026.
  • Citadel Advisors sold 122,679 Context Therapeutics shares in Q2 2026, an estimated $249K.
  • Context Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13501 holding.
  • Citadel Advisors first reported a position in Context Therapeutics in Q1 2022 and has held it in 9 quarters since.
  • Citadel Advisors's Context Therapeutics position peaked at $367K in Q1 2026.
  • 79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.